106 Dividend Sensei – Why You (And Another Company) Should Buy Gilead

Adam, the “Dividend Sensei” and I sit down to do some Gilead stock research (GILD). Adam provides a fire hydrant blast of information and expectations regarding Gilead, including some thoughts on the possibility of Gilead being acquired.

(Press play button to listen or click here to download.)

Subscribe: iTunes | Android | RSS

I’d like to see more content like this!

gilead stock research

If you’d like to jump ahead in the interview to the discussion on Gilead’s acquisition prospects, it begins around the 20 minute mark of the interview.

A quick overview:

  • Gilead’s free cash flow prospects.
  • Company’s track record, culture, R&D, manufacturing process, patent portfolio, and pipeline.
  • Adam’s price targets for Gilead.
  • Who might purchase Gilead and for how much.
  • How he plans to respond if price falls any further.
  • Much more…

Companies Mentioned: Pfizer (PFE), JNJ (JNJ), Merck (MRK), Amgen (AMGN), AstraZeneca (AZN), AbbVie (ABBV)

I hope you enjoy this interview.



Content You’ll Also Like

105 Aurelien Windenberger – When SolarCity Will Run Out of Money

104 Richard Berger – The Coming Bear and How to Prepare

103 Leo Nelissen – How to Use the ISM Index and Durable Goods Report

106 Dividend Sensei – Gilead Stock Research – Why You Should Buy Gilead Stock

Gilead Stock Research

Find more from Dividend Sensei.

Family Investor